Study Design. We investigated the association between ICAM-1, -2, -3 plasma levels and ankylosing spondylitis (AS) disease activity.
A nkylosing spondylitis (AS) is a chronic autoimmune inflammatory disease that affects the axial skeleton and the sacroiliac joints, leading to bone erosion, which seriously influences the quality life of patients. 1 The main symptoms of AS are inflammatory pain and morning stiffness because of inflammation of the spine, which leads to a significant limitation of mobility and ongoing pain during the active stages of the disease. 2 Since disease activity is closely related to therapy and prognosis, for decades, people have looked for a comprehensive and practical approach to evaluate AS disease activity. Currently, radiographic imaging is the most popular and convenient method used in the diagnosis and prognosis of AS. However, only severe AS-induced spinal damage can be identified radiographically, 3 which cannot effectively assess disease activity. Meanwhile, assessment such as the Bath ankylosing spondylitis disease activity index (BASDAI) and ankylosing spondylitis disease activity score (ASDAS) that are used to assess AS disease activity clinically at present are often highly subjective, and do not completely reflect the complexity of the disease. Thus, understanding the molecular progression of AS would help to keep abreast of disease activity and treatment during pathogenesis.
The pathogenic process and severity of AS depend on the degree of inflammation in the disease. 4 There are many proinflammatory cytokines and surface molecules involved in the inflammatory process of AS, such as tumor necrosis factor-a (TNF-a) and interleukin-1 (IL-6), as well as intercellular adhesion molecules (ICAMs). 5 The ICAMs are part of the immunoglobulin superfamily, and play important roles in inflammation, immune responses, and intracellular signaling events. 6 The ICAM family consists of five members, designated ICAM-1 to ICAM-5. They are known to attract inflammatory cells by recognizing and adhering to them during inflammation and take part in the immune response. However, the correlation between ICAM concentrations and AS disease activity has not been reported.
ICAM-1, also known as CD54, is a type of glycoprotein continuously present in low concentrations on the membrane of leukocytes and endothelial cells. ICAM-1 can be induced by IL-1 and TNF-a and is expressed by the vascular endothelium, macrophages, and lymphocytes. ICAM-1 participates in a variety of chronic inflammatory processes. Studies have shown that ICAM-1 can be upregulated by inflammatory cytokines during inflammation of the airway epithelium and is involved in lung inflammation. 7 It also contributes to the initiation of systemic inflammation in neonatal sepsis 8 and is directly involved in viral inflammation processes, such as rhinovirus infection of the airways. 9 In AS patients, increased ICAM-1 levels are often considered to be associated with higher risk of cardiovascular disease. 10 ICAM-2 (CD102) has been reported to play a role in lymphocyte recirculation by blocking lymphocyte function-associated antigen-1 (LFA-1)-dependent cell adhesion. 11 It also mediates adhesive interactions for antigen-specific immune responses, NK-cell mediated clearance, lymphocyte recirculation, and other cellular interactions for immune response and surveillance. ICAM-3, also called CD50, is constitutively and abundantly expressed by leukocytes and may be the most important ligand for LFA-1 in the initiation of the immune response. 12 The functions of the other two ICAMs, ICAM-4 and ICAM-5, are rarely reported. ICAM-4 appears to be restricted to erythroid cells, whereas ICAM-5 may be a critical component in neuronmicroglial cell interactions in the course of normal development or as part of neurodegenerative diseases; these ICAMs have not been assessed in this study.
Therefore, on the basis of the chronic inflammatory reaction during AS progression, and the relationship between ICAM-1, ICAM-2, ICAM-3, and inflammatory responses, we speculated that these ICAMs may serve as potential biomarkers of AS disease activity. Here, we investigated plasma levels of ICAM-1, -2, -3 in the Chinese Han population with AS as compared with healthy controls, and explored their relationship to proinflammatory cytokines release, laboratory parameters, and AS disease activity.
MATERIALS AND METHODS

Study Populations
This case-control study was approved by the Ethical Committee of Henan Province Hospital of Traditional Chinese Medicine (TCM), China. All patients and control subjects provided written informed consent to participate after a full explanation of the study From June 2014 to May 2015, 60 consecutive patients with AS (53 HLA-B27-positive, 7 HLA-B27-negative; 41 men and 19 women) according to the modified 1984 New York criteria for AS diagnosis 13 and 60 healthy controls (39 men and 21 women) undergoing routine health examinations in the corresponding time period were recruited from Henan Province Hospital of TCM. Patients were excluded if they had bone disease other than AS, clinical or radiographic evidence of complete spinal ankylosis, or a history of recurrent infections or cancer or a serious liver, renal, hematological, or neurological disorder. None of the patients were receiving anti-TNFs to facilitate the analysis of the criteria for inflammatory activity. In addition, healthy subjects who had an AS history, AS family history, or other serious cardiac, brain, and kidney diseases were excluded. All these subjects were from the Chinese Han population and were recruited in an attempt to provide a similar genetic and environmental background to the patient population.
Clinical and Biochemical Assessment
Clinical assessment of disease activity was evaluated by using the Bath ankylosing spondylitis disease activity index (BASDAI) and the AS disease activity score (ASDAS). Functional ability was monitored using the Bath ankylosing spondylitis functional index (BASFI).
14 Biochemical analysis of the erythrocyte sedimentation rate (ESR) was performed by the Westergren method and plasma C-reactive protein (CRP) levels were determined by immunoturbidimetry (immunological turbidity kit for human C-reactive protein, Beckman Coulter IMMAGE 800, Brea, California, USA). The assays were performed according to the manufacturer's instructions. All samples were examined in duplicate.
Estimation of Proinflammatory Cytokines and ICAM Levels
Blood samples were collected from the antecubital vein of patients and controls. The blood samples were immediately anticoagulated with 2% ethylenediaminetetraacetic acid (EDTA) disodium after collection and plasma samples were separated after centrifugation at 48C, 2000 g for 10 minutes, and stored at À808C until analysis. Plasma levels of the proinflammatory cytokines TNF-a and IL-6 were assessed using standard enzyme-linked immunosorbent assay (ELISA) kits from CUSABIO (Wuhan, China). Since ICAMs may exist in a soluble form in human plasma, because of activation and proteolysis mechanisms at cell surfaces, ICAM levels were estimated by detecting the plasma levels of sICAM. The sICAM-1, -2, -3 concentrations were determined using corresponding ELISA kits purchased from eBioscience (San Diego, CA) according to the manufacturer's recommendations. All samples were measured in duplicate.
Statistical Analysis
The results obtained in this study are expressed as mean value AE standard deviation (SD) (quantitative variables) or as frequencies and percentages (qualitative variables). Differences between two groups with quantitative variables were assessed with the independent samples t test, whereas these with qualitative variables were assessed with the Mann-Whitney U test for nonparametric data. Correlation analyses were carried out using Pearson's rank correlation test and P < 0.05 was considered statistically significant. All statistical analyses were conducted using Statistical Package for Social Sciences (SPSS) 13.0 software Chicago, Delaware, USA for Windows.
RESULTS
Characteristics of the Study Population
The demographic characteristics of the patients and healthy controls are summarized in Table 1 . This study included 60 AS patients (41 men and 19 women) aged 34 AE 15 years, and 60 controls (39 men and 21 women) aged 33 AE 12 years; there was no difference in age between the two groups. The height, body weight, body mass index (BMI) were also assessed, revealing no significant differences between AS patients and the control group (P > 0.05).
It has become clear that AS is a chronic inflammatory disease. Consistent with this point, our results show that the levels of plasma TNF-a, IL-6, CRP, and ESR, which are known as inflammatory biomarkers, were significantly higher in AS patients, compared with the levels in healthy controls (P < 0.0001); the BASDAI (5.2 AE 2.1), BASFI (4.7 AE 2.4), and ASDAS (2.5 AE 1.3) scales showed high disease activity in the AS patients (Table 2) .
Plasma Levels of ICAMs in Patients With AS
To evaluate the involvement of ICAMs in AS, we compared the plasma levels of ICAM-1, -2, -3 in AS patients and healthy controls. ELISA analysis showed that the plasma levels of ICAM-1 and ICAM-2 were greatly increased in AS patients compared with healthy controls (AS vs. healthy control, 641.25 AE 64.34 vs. 232.89 AE 87.13, 697.75 AE 59.41 vs. 436.47 AE 70.30, P < 0.0001; Figure 1 A and B) . There was also an increase in the plasma level of ICAM-3 in patients compared with that of controls, but this increase was not significant (312.33 AE 69.16 vs. 286.38 AE 58.98, P > 0.05; Figure 1C) . The results suggest that increased ICAM-1 and ICAM-2 levels in plasma might be associated with AS.
Positive Correlation Between ICAM-1, -2 Levels and Proinflammatory Cytokine Secretion and Biochemical Indicators in AS Patients
Univariate correlation analysis showed that the plasma levels of both ICAM-1 and ICAM-2 were positively correlated with the secretion of proinflammatory cytokines TNF-a (r 2 ¼ 0.1924, P ¼ 0.0005; r 2 ¼ 0.6616, P < 0.0001) (Figure 2A and E) , IL-6 (r 2 ¼ 0.1881, P ¼ 0.0005; r 2 ¼ 0.4374, P < 0.0001) ( Figure 2B and F) , as well as the biochemical indicators CRP (r 2 ¼ 0.3775, P < 0.0001; r 2 ¼ 0.8200, P < 0.0001) ( Figure 2C and G), and ESR (r 2 ¼ 0.2835, P < 0.0001; r 2 ¼ 0.7236, P < 0.0001) ( Figure 2D and H) ( Table 3) .
Positive Correlation Between ICAM-1, -2 Levels and Disease Activity in AS Patients
BASDAI, BASFI, and ASDAS are general assessments of the severity and activity of AS. In our study, all of the patients with AS were required to fill in the BASDAI BASFI, and ASDAS forms. The correlations were analyzed between the BASDAI, BASFI, ASDAS values and ICAM-1, -2 levels in plasma. The data show that there were no significant associations between ICAM-1 levels and BASDAI (r 2 ¼ 0.0570, P ¼ 0.0663) ( Figure 3A ), BASFI (r 2 ¼ 0.0471, P ¼ 0.0959) ( Figure 3B ), or ASDAS (r 2 ¼ 0.0212, P ¼ 0.2676) ( Figure 3C ). However, BASDAI was positively correlated with plasma levels of ICAM-2 (r 2 ¼ 0.5743, P < 0.0001) ( Figure 3D ), as were BASFI (r 2 ¼ 0.4421, P < 0.0001) ( Figure 3E ) and ASDAS (r 2 ¼ 0.5215, P < 0.0001) ( Figure 3F ) in AS patients (Table 4) . These data further indicate that ICAM-2 is involved in the development of AS, and might be used as a potential biomarker reflecting disease activity and functional ability in AS patients. 
DISCUSSION
AS is a chronic inflammatory disease with unclear etiology and pathogenesis. Because of the inconspicuous symptoms of AS, patients are often diagnosed many years after the original onset, with irreversible damage to the joints. Therefore, there is an urgent need for early diagnosis and a more exact understanding of AS disease activity. Evidence to date suggests that an imbalance in immune cells and resulting aberrant cytokine secretion are involved in the pathogenesis of AS, 15 and the onset, pathogenic process, and severity of AS are dependent on the degree of inflammation in the disease. 1 ICAMs have been used as biomarkers of endothelial cell dysfunction; moreover, a higher risk of cardiovascular events has been reported to be correlated with TNF-a and IL-6 release and T-cell activity in a variety of chronic inflammatory diseases. 16 Dustin et al 17 systematically evaluated the distribution and expression of ICAM-1 in the body and found high expression by inflammatory and dendritic cells in germinal centers and T-cell areas in lymphoid tissues. These cells are considered to play important roles in immune and inflammatory responses. Studies have shown that both ICAM-1 and ICAM-2 can promote the migration, extravasation, and attachment of inflammatory cells to various tissue components. The modulation of ICAM-1 by IL-1 and TNF-g, which facilitate the adhesion of lymphocytes, macrophages, and natural killer cells to ductal epithelial cells, facilitates the elimination of epithelial cells damaged by marked inflammation. 18 In the present study, we speculated that ICAMs may be potential biomarkers of AS disease activity, and thus illustrated the correlations between ICAM-1, -2, -3 levels and proinflammatory cytokine release, laboratory parameters, and AS disease activity in AS patients of the Chinese Han population.
Several studies have demonstrated the potential value of measuring serum ICAM levels in diagnosing endothelial dysfunction, atherosclerosis, and the risk of cardiovascular disease. 19 However, few clinical trials to date have assessed plasma ICAM levels, especially ICAM-2 and ICAM-3, in AS patients. Our data in this case-control study show a statistically significant increase in the plasma levels of both ICAM-1 and ICAM-2 in AS patients compared with healthy controls. Elevated levels of ICAM-1 expression may be a response to inflammation, 20 whereas increased ICAM-2 levels may indicate the activation of various T-cell subsets. 21 One previous study showed that ICAM-3 might combine with LFA-1 and act as a recognition receptor in the phagocytosis portals of macrophages to promote the engulfment of apoptotic neutrophils, 22 and thereby take part in the immune reaction. In this study, there was an increase in the plasma level of ICAM-3, but no difference was found between controls and patients. These results suggest that increased ICAM-1 and ICAM-2, but not ICAM-3 levels in plasma may be associated with the pathogenesis of AS and disease activity.
Although the mechanism of pathogenesis in AS is poorly understood, the published data have indicated that proinflammatory cytokines play an important role in the inflammatory development of AS. 23 Previous studies have demonstrated that serum levels of TNF-a and IL-6 are significantly elevated in AS patients. 24 ,25 IL-6 serum levels were found to be positively correlated with spinal inflammation in AS patients. 26 Moreover, TNF-a expression has been found to be greatly increased in the sacroiliac joint. 27 In addition, clinical trials suggest that blocking these cytokines can partly relieve the inflammatory symptoms of AS and also appear to reduce disease severity. 28, 29 To explore whether the higher plasma levels of ICAM-1 and ICAM-2 are associated with the severity of AS, the Pearson's rank correlation test was performed to assess the relationship between sICAM-1, sICAM-2 and TNF-a and IL-6 release in AS patients. The results show that both plasma ICAM-1 and ICAM-2 concentrations were positively correlated with TNF-a and IL-6 levels. Moreover, the plasma levels of ICAM-1 and ICAM-2 also exhibited remarkable positive correlations with ESR and CRP, both of which are regarded as common markers of AS.
The BASDAI, BASFI, and ASDAS scales are used as clinical indicators of disease activity. 30 One previous study reported that serum levels of ICAM-1 are positively correlated with the presence of factors such as HBP, DBP, dyslipidemia, smoking, and CAD Hx, but not with disease activity in AS. 31 Moreover, another study showed that circulating sICAM-1 can be considered a biomarker of infection and prognosis in patients with systemic inflammatory response syndrome. 32 Thus, we further analyzed the relationship between ICAM-1 and ICAM-2 expression and AS disease activity assessed by BASDAI, BASFI, and ASDAS. Interestingly, although significant correlations were found between plasma ICAM-1 levels and ESR and CRP levels, the results failed to find such relationships between ICAM-1 levels and the scores of BASDAI, BASFI, and ASDAS in AS patients. The lack of a relationship between serum ICAM-1 and disease activity in AS could be explained by the fact that it acts locally in the joints and bones with no systemic effects. It also suggests that inflammation in patients with AS, might have an impact on chronic changes in AS joints with no influence on disease activity. However, all of the disease severity-related indexes showed remarkable positive correlations with plasma ICAM-2 levels.
In summary, this is the first attempt to evaluate the correlations between ICAM-1, -2, and -3 concentrations and disease activity in AS. Our results revealed increased plasma ICAM-1, and ICAM-2 levels in AS patients, suggesting a potential role in the pathogenesis of AS. Both ICAM-1 and ICAM-2 are associated with proinflammatory cytokine levels and laboratory parameters, and a correlation between plasma ICAM-2 levels and the BASDAI, BASFI, and ASDAS scores was observed in this study. Therefore, ICAM-2 may be used as a valuable biomarker to assess the progression of AS. There are limitations of the present study, for example, the small sample size, which may have biased the results. Moreover, the mechanism of ICAM Key Points ICAM-1, -2 levels were positively correlated with proinflammatory cytokine secretion and biochemical indicators. ICAM-2 levels were positively correlated with AS disease activity. ICAM-2 might be used as a potential biomarker reflecting disease activity and functional ability. 
